Heart leiomyosarcoma

disease
On this page

Also known as Cardiac leiomyosarcomaleiomyosarcoma of heartleiomyosarcoma of the heart

Summary

Heart leiomyosarcoma (MONDO:0003353) is a disease. A subtype of heart sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameheart leiomyosarcoma
Mondo IDMONDO:0003353
DOIDDOID:5261
NCITC5364
UMLSC1332848
MedGen234095
GARD0023468
Anatomy (UBERON)UBERON:0000948
Is cancer (heuristic)no

Also known as: Cardiac leiomyosarcoma · heart leiomyosarcoma · leiomyosarcoma of heart · leiomyosarcoma of the heart

Disease family

This is a subtype of heart sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmcancercardiovascular cancerheart cancerheart sarcomaheart leiomyosarcoma

Related subtypes (2): malignant cardiac peripheral nerve sheath neoplasm, heart fibrosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.